Direct activation of the high-affinity nerve growth factor receptor by a non-peptide symmetrical polyanion

Neuroscience

Volumn 87, Issue 4, 1998, Pages 855-860

  Gill, J S ^a   Windebank, A J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Neurite outgrowth; PC12 cells; Receptor dimerization; Suramin; Tyrosine phosphorylation

Indexed keywords

ANTINEOPLASTIC AGENT; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; POLYANION; POLYCLONAL ANTIBODY; SURAMIN; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DIMERIZATION; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR AFFINITY; SPINAL GANGLION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBODIES; DIMERIZATION; ENZYME ACTIVATION; GROWTH INHIBITORS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PC12 CELLS; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR; SIGNAL TRANSDUCTION; SURAMIN;

EID: 0032543983     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00206-1     Document Type: Article

References (25)

1. Blexrud M. D., Lee D. A., Windebank A. J., Brunden K. R. Kinetics of production of a novel growth factor after peripheral nerve injury. J. neurol. Sci. 98:1990;287-299.
2. Cardinali M., Sartor O., Robbins K. C. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. J. clin. Invest. 89:1992;1242-1247.
3. Coffey R. J., Leof E. B., Shipley G. D., Moses H. L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J. Cell Physiol. 132:1987;143-148.
4. De Clercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. 8:1979;9-22.
5. Eisenberger M. A., Reyno L. M., Jodrell D. I., Sinibaldi V. J., Tkaczuk K. H., Sridhara R., Zuhowski E. G., Lowitt M. H., Jacobs S. C., Egorin M. J. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J. natn. Cancer Inst. 85:1993;611-621.
6. Fuglsang H., Anderson J. Side effects of suramin. Sci. Publ. Pam. Am. Health Organ. 298:1974;54-56.
7. Gill J. S., Connolly D. C., McManus M. J., Maihle N. J., Windebank A. J. Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons. J. Neurochem. 66:1996;963-972.
8. Hawking F. Suramin: with special reference to onchocerciasis. Adv. Pharmac. Chemother. 15:1978;289-322.
9. Horne M. K. III, Stein C. A., LaRocca R. V., Myers C. E. Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood. 71:1988;273-279.
10. Jackson T. R., Blader I. J., Hammonds-Odie L. P., Burga C. R., Cooke F., Hawkins P. T., Wolf A. G., Heldman K. A., Theibert A. B. Initiation and maintenance of NGF-stimulated neurite outgrowth requires activation of a phosphoinositide 3-kinase. J. Cell Sci. 109:1996;289-300.
11. Kaplan D. R., Martin-Zanca D., Parada L. F. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 350:1991;158-160.
12. LaRocca R. V., Cooper M. R., Uhrich M., Danesi R., Walther M. M., Linehan W. M., Myers C. E. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol. Clin. North Am. 18:1991;123-129.
13. LaRocca R. V., Meer J., Gilliatt R. W., Stein C. A., Cassidy J., Myers C. E., Dalakas M. C. Suramin-induced polyneuropathy. Neurology. 40:1990;954-960.
14. LaRocca R. V., Stein C. A., Myers C. E., Dalakas M., McAtee N. Suramin induced acute polyneuropathy. Proc. Ann. Meet. Am. Soc. clin. Oncol. 8:1989;71.
15. Lehmann S., Quirosa-Guillou C., Becherer U., Thal C., Zanetta J.-P. Neurite outgrowth of neurons of rat dorsal root ganglia induced by new neurotrophic substances with guanidine group. Neurosci. Lett. 152:1993;57-60.
16. Mills G. B., Zhang N., May C., Hill M., Chung A. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. Cancer Res. 50:1990;3036-3042.
17. Ohmichi M., Pang L., Ribon V., Gazit A., Levitzki A., Saltiel A. R. The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. Biochemistry. 32:1993;4650-4658.
18. Pollak M., Richard M. Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells [published erratum appears in J. natn. Cancer Inst. (1990) 82, 1510]. J. natn. Cancer Inst. 82:1990;1349-1352.
19. Pradines A., Magazin M., Schiltz P., Le Fur G., Caput D., Ferrara P. Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J. Neurochem. 64:1995;1954-1964.
20. Russell J. W., Windebank A. J., Podratz J. L. Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann. Neurol. 36:1994;221-228.
21. Scher H. I., Jodrell D. I., Iversen J. M., Curley T., Tong W., Egorin M. J., Forrest A. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 52:1992;64-70.
22. Soltoff S. P., Rabin S. L., Cantley L. C., Kaplan D. R. Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase. J. biol. Chem. 267:1992;17472-17477.
23. Stein C. A. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 53:1993;2239-2248.
24. Stein C. A., LaRocca R. V., Thomas R., McAtee N., Myers C. E. Suramin: an anticancer drug with a unique mechanism of action. J. clin. Oncol. 7:1989;499-508.
25. Vetter M. L., Martin-Zanca D., Parada L. F., Bishop J. M., Kaplan D. R. Nerve growth factor rapidly stimulates tyrosine phosphorylation of phospholipase C-γ1 by a kinase activity associated with the product of the trk protooncogene. Proc. natn. Acad. Sci. U.S.A. 88:1991;5650-5654.